Vaccine

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Tailored Vaccines: With the AI-Immunology™ enabled discovery of these novel types of cancer vaccine targets, designing personalized and precision vaccine…

11 months ago

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T…

11 months ago

ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation

 Novel HIV vaccine candidate based on Gorilla adenoviral vector (GRAd-HIV) funded by the Bill & Melinda Gates Foundation to alleviate…

11 months ago

Defence Financing

Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the…

11 months ago

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

- 10,000-subject Phase 2b study would evaluate Vaxart’s next generation oral pill XBB COVID-19 vaccine against an approved mRNA vaccine…

11 months ago

Imugene’s CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium

SYDNEY, AUSTRALIA / ACCESSWIRE / January 18, 2024 / Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to…

11 months ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker…

11 months ago

Gritstone bio to Participate in Upcoming Investor Conference

EMERYVILLE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop…

11 months ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing…

11 months ago